CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6218 result(s)

budesonide (Jorveza )

Last Updated: November 20, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: budesonide
Indications: Indicated for the induction and maintenance of clinico-pathological remission in adults with eosinophilic esophagitis (EoE).

  • Brand Name: Jorveza
  • Manufacturer: AVIR Pharma Inc
  • Project Number: SR0666-000
  • Project Status: Active
  • Submission Type: Initial

ranolazine (TBC)

Last Updated: November 18, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: ranolazine
Indications: Indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (such as beta-blockers and/or calcium antagonists). Ranolazine may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers

  • Brand Name: TBC
  • Manufacturer: KYE Pharmaceuticals Inc.
  • Project Number: SR0655-000
  • Project Status: Active
  • Submission Type: Initial

amifampridine (Ruzurgi)

Last Updated: November 23, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: amifampridine
Indications: Indicated for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 years of age and older.

  • Brand Name: Ruzurgi
  • Manufacturer: Médunik Canada Inc.
  • Project Number: SR0660-000
  • Project Status: Active
  • Submission Type: Initial

etonogestrel (Nexplanon)

Last Updated: November 20, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: etonogestrel
Indications: Indicated for the prevention of pregnancy for up to 3 years

  • Brand Name: Nexplanon
  • Manufacturer: Merck Canada Inc.
  • Project Number: SR0648-000
  • Project Status: Active
  • Submission Type: Initial

fremanezumab (Ajovy)

Last Updated: November 19, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: fremanezumab
Indications: ​Indicated for the prevention of migraine in adults who have at least 4 migraine days per month.

  • Brand Name: Ajovy
  • Manufacturer: Teva Canada Innovation
  • Project Number: SR0641-000
  • Project Status: Active
  • Submission Type: Initial

Nivolumab-Ipilimumab (Opdivo-Yervoy)

Last Updated: November 23, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: nivolumab-ipilimumab
Indications: ​OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.

  • Brand Name: Opdivo-Yervoy
  • Manufacturer: Bristol-Myers Squibb
  • Project Number: PC0229-000
  • Project Status: Active
  • Submission Type: Initial

dinutuximab (Unituxin)

Last Updated: November 23, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: dinutuximab
Indications: For the treatment of pediatric patients with relapsed/refractory high-risk neuroblastoma in combination with irinotecan, temozolomide, and granulocyte macrophage colony-stimulating factor.

  • Brand Name: Unituxin
  • Manufacturer: United Therapeutics Corp.
  • Project Number: PC0222-000
  • Project Status: Received
  • Submission Type: Initial

chlormethine hydrochloride (Ledaga)

Last Updated: November 23, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: chlormethine hydrochloride
Indications: For the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients.

  • Brand Name: Ledaga
  • Manufacturer: Recordati Rare Diseases Canada Inc.
  • Project Number: PC0242-000
  • Project Status: Pending
  • Submission Type: Initial

COVID-19 Update

Last Updated: November 23, 2020
Result type: Reports
Product Line: New at CADTH

CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time. Our COVID-19 evidence portal contains the latest COVID-19 information from CADTH and other respected organizations. Content is updated daily to reflect the rapidly changing and growing state of the international scientific evidence...